首页> 外文期刊>Cephalalgia >Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats.
【24h】

Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats.

机译:慢性舒马曲坦和佐米曲坦治疗对大鼠5-HT受体表达和功能的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Reuter U, Salomone S, Ickenstein GW & Waeber C. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT(1) receptor expression and function in rats. Cephalalgia 2004. London. ISSN 0333-1024Triptans are commonly used anti-migraine drugs and show agonist action mainly at serotonin 5-HT(1B/1D/1F) receptors. It is not known whether frequent or long-term treatment with these drugs would alter 5-HT receptor function. We investigated the effects of protracted (14-18 days) sumatriptan and zolmitriptan treatment in rats on 5-HT(1) receptor mRNA expression and function in tissues related to migraine pathophysiology. RT-PCR analysis revealed that 5-HT(1B/1D/1F) receptor mRNA was reduced in the trigeminal ganglion after treatment with either triptan (reduction by: sumatriptan 39% and zolmitriptan 61% for 5-HT(1B); 60%vs 41% for 5-HT(1D); 32%vs 68% for 5-HT(1F)). Sumatriptan attenuated 5-HT(1D) receptor mRNA by 49% in the basilar artery, whereas zolmitriptan reduced 5-HT(1B) mRNA in this tissue by 70%. Nochange in 5-HT(1) receptor mRNA expression was observed in coronary artery and dura mater. Chronic triptan treatment had no effect in two functional assays [sumatriptan mediated inhibition (50 mg/kg, i.p.) of electrically induced plasma protein extravasation in dura mater and 5-nonyloxytryptamine-stimulated [(35)S]guanosine-5'-O-(3-thio)triphosphate binding in substantia nigra]. Furthermore, vasoconstriction to 5-HT in isolated basilar artery was not affected by chronic triptan treatment, while it was slightly reduced in coronary artery. We conclude that, although our treatment protocol altered mRNA receptor expression in several tissues relevant to migraine pathophysiology, it did not attenuate 5-HT(1) receptor-dependent functions in rats.
机译:Reuter U,Salomone S,Ickenstein GW和Waeber C.慢性舒马曲坦和佐米曲普坦治疗对大鼠5-HT(1)受体表达和功能的影响。 Cephalalgia2004。伦敦。 ISSN 0333-1024 Triptans是常用的抗偏头痛药物,主要对5-羟色胺5-HT(1B / 1D / 1F)受体显示激动剂作用。尚不清楚这些药物的频繁或长期治疗是否会改变5-HT受体的功能。我们调查了舒马曲坦和佐米曲普坦治疗大鼠(14-18天)对5-HT(1)受体mRNA表达和偏头痛病理生理相关组织功能的影响。 RT-PCR分析显示,使用任何曲普坦治疗后,三叉神经节中5-HT(1B / 1D / 1F)受体mRNA均降低(5-HT(1B)的舒马曲坦39%和佐米曲坦61%降低; 60% vs 5-HT(1D)为41%; 5-HT(1F)为32%vs 68%)。苏门曲普坦使基底动脉中的5-HT(1D)受体mRNA降低49%,而佐米曲普坦使该组织中的5-HT(1B)mRNA降低70%。在冠状动脉和硬脑膜中观察到5-HT(1)受体mRNA表达没有变化。慢性曲普坦治疗在两种功能测定[舒马曲坦介导的硬脑膜电刺激血浆蛋白渗出和5-壬基氧色胺刺激的[(35)S]鸟苷-5'-O-抑制(50 mg / kg,ip)中没有作用。 (3-硫代)三磷酸结合在黑质中]。此外,慢性曲坦治疗不影响离体基底动脉对5-HT的血管收缩,而在冠状动脉中血管收缩稍有减少。我们得出的结论是,尽管我们的治疗方案改变了与偏头痛病理生理相关的几个组织中的mRNA受体表达,但它并未减弱大鼠的5-HT(1)受体依赖性功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号